IGM-IFOM Joint Seminars – Giorgia Zadra

May 20th, 2021 at 14:30

Giorgia Zadra, Researcher at the IGM, on:

The Fats and The Furious

Metabolic rewiring fuels aggressive prostate cancer: clinical implications

Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice.

This work identifies tocilizumab, a neutralizing antibody already exploited in clinical applications, as a valuable therapeutic tool in Hutchinson-Gilford progeria, a disease that causes premature ageing. Data here reported further suggest to explore tocilizumab as a potential treatment for aging-related disorders. The study has been designed and coordinated by CNR IGM Bologna Unit.

 

Squarzoni S, Schena E, Sabatelli P, Mattioli E, Capanni C, Cenni V, D’Apice MR, Andrenacci D, Sarli G, Pellegrino V, Festa A, Baruffaldi F, Storci G, Bonafe’ M, Barboni C, Sanapo M, Zaghini A, Lattanzi G. (2021) Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice. Aging Cell, 20(1):e13285. doi: 10.1111/acel.13285

Joining European Scientific Forces to Face Pandemics

Despite the international guidelines on the containment of the COVID-19 pandemic, the European scientific community was not sufficiently prepared to coordinate scientific efforts. To improve preparedness for future pandemics, nine groups of scientists already funded by the European program for Cooperation in Science and Technology (COST), coordinated by Chiara Rignati from Turin University, joined in a network, called Trans-COST Action COVID-19, to facilitate inter-, multi-, and trans-disciplinary communication and collaboration nin order to set-up research strategies and preclinical models for the study of viruses, vaccines and anti-viral drugs. 

Giovanna Lattanzi of CNR IGM, is part of the management committee of the EuroCellNet COST Action and, along with the action coordinator Pavel Hozak and colleagues from the other COST actions, contributed to drafting of the proposals.

 

Vasconcelos MH, Alcaro S, Arechavala-Gomeza V, Baumbach J, Borges F, Brevini TAL, Rivas JL, Devaux Y, Hozak P, Keinanen-Toivola MM, Lattanzi G, Mohr T, Murovska M, Prusty BK, Quinlan RA, Perez-Sala D, Scheibenbogen C, Schmidt HHHW, Silveira I, Tieri P, Tolios A, Riganti C. (2021) Joining European Scientific Forces to Face Pandemics. Trends in microbiology. 29(2):92-97. doi: 10.1016/j.tim.2020.10.008

IGM-IFOM Joint Seminars – Marco Foiani

The next IGM-IFOM seminar will ben on May 6th, at 14:30

The speaker Marco Foiani, Scientific Director of IFOM, entitled: 

“Mechanism controlling Genome and Nuclear Integrity”

DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects

Mutations in BRCA1 and BRCA2 tumor suppressor genes predispose individuals to breast and ovarian cancers. These cancers are treated in the clinic with platinum drugs and inhibitors of polyADP-ribose polymerase (PARP), which cause lesions requiring homologous recombination repair activities mediated by BRCA1 and BRCA2. However, BRCA1 and BRCA2 tumors often acquire resistance to chemotherapy, either by somatic reversion or by acquiring homologous recombination proficiency, leading to aggressive tumor growth.

Thus, there is an urgent need to identify ways to potentiate the therapy and overcome acquired resistance of homologous recombination-deficient cancer cells. In a recent work, published in Proceedings of the National Academy of Science USA (PNAS) by researchers of IGM and IFOM, Dana Branzei and Nanda Kumar Jegadesan identify that the helicase DDX11 is critical to mitigate replication stress in a range of cancers by facilitating upstream steps in homologous recombination repair related to efficient resection of double strand breaks. Importantly, DDX11 acts in manners non-redundant with BRCA1 and BRCA2. Strikingly, this study shows thar targeting DDX11 improves chemotherapy response in both chemotherapy sensitive and drug-resistant BRCA1/2-mutated cancers that regained homologous recombination proficiency by suppressor mutation or somatic reversion. Thus, DDX11 provides a mechanism of replication stress tolerance in cancers, a finding that can be exploited therapeutically in the future through the development of specific inhibitors of DDX11 helicase activity.

 

Nanda Kumar Jegadesan and Dana Branzei. DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects. Proc Natl Acad Sci, doi:10.1073/pnas.2024258118.

 

IGM-IFOM Joint Seminars – Paolo Colombi

The next IGM-IFOM seminar will ben on April 22nd, at 14:30

The speaker Paolo Colombi, IFOM, will present the seminars entitled: 

“Lem domain proteins control adaptation efficiency through copy number variations”

IGM-IFOM Joint Seminars – Andrea Ciliberto

The next IGM-IFOM seminar will ben on April 8th, at 14:30

The speaker Andrea Ciliberto, IFOM, will present the seminars entitled: 

“Stopping the unstoppable: how cells react to stimuli impairing cell proliferation”

 

CONGRATULATIONS DR. BASSO!

It is with great affection that the researchers and all colleagues at IGM do congratulate Sammy Basso on his master’s degree in Molecular Biology achieved on March 24 at the University of Padua. One more time we like to remember with gratitude all the years of collaboration between IGM and AIPROSAB and Sammy’s commitment to the Italian Network for Laminopathies. But above all we want to remember the friendship born between Sammy and us of the IGM in Bologna, the wonderful period of the Sammy’s internship in IGM, despite the misadventure of the pandemic, the Sammy commitment in the preparation of his thesis and the enthusiasm he had in our scientific discussions.